Eurotimes Articles

Exclusive partnership

Posted in:

SCHWIND eye-tech-solutions, Germany, has announced an exclusive partnership with ALPHAEON Corporation, US. SCHWIND has granted ALPHAEON the exclusive license to market SCHWIND AMARIS technology in the US. As part of the relationship, ALPHAEON will oversee and finance the US Food and Drug Administration (FDA) clinical trial required to market the product in the US. ALPHAEON, a wholly-owned subsidiary of Strathspey Crown Holdings LLC, closely cooperates with American eye surgeons to bring highly developed technologies to the US market. SCHWIND chief executive officer Rolf Schwind (pictured) said: “This cooperation is a historical milestone in the SCHWIND company history and for us, as a medium-sized family company, the best possible strategy to establish our cutting-edge technology in North America without entrepreneurial risks. We strongly believe that our partnership with ALPHAEON will build customer confidence and significantly impact the growth of patient procedures.”

Back to Previous

Popular Items